Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC:

Daniela Bianconi,Merima Herac,Florian Posch,Margit Schmeidl,Matthias Unseld,Markus Kieler,Robert Brettner,Leonhard Müllauer,Jakob M. Riedl,Armin Gerger,Werner Scheithauer,Gerald W. Prager

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC:

2020

Daniela Bianconi
Merima Herac
Florian Posch
Margit Schmeidl
Matthias Unseld
Markus Kieler
Robert Brettner
Leonhard Müllauer
Jakob M. Riedl
Armin Gerger
Werner Scheithauer
Gerald W. Prager

Background:Targeted therapies offer novel opportunities to explore biomarkers based on their mode of action. Taking this into consideration, we evaluated six angiogenesis-related proteins as potent...

Keywords:

Medicine
Oxaliplatin
Capecitabine
Biomarker (medicine)
Internal medicine
Bevacizumab
Phases of clinical research
Oncology
Colorectal cancer
Irinotecan
Angiogenesis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations